Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptide Blends: Research Dosing Protocols Index - Peptide Dosages

Peptide Blends Pre-mixed multi-peptide blends in one vial — reconstitution math and dosing worked out for each strength. Example — click the calculator icon on any vial size below to load its BAC water and starting dose, or edit the fields. On a U-100 insulin

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Peptide Blends

Pre-mixed multi-peptide blends in one vial — reconstitution math and dosing worked out for each strength.

Example — click the calculator icon on any vial size below to load its BAC water and starting dose, or edit the fields.

On a U-100 insulin syringe, 100 units = 1 mL. For research use — always confirm against the protocol page.

No protocols match your filters

Try a different search term, goal or category.

Request a custom protocol

If a peptide or vial strength isn't listed yet, we'll build the reconstitution and dosing guide for it — free.

All peptide dosage protocols

Every single-peptide, blend and stack protocol on Dosage Peptide, grouped by category.

Bioregulators

Cardiogen · 20 mg

Cartalax · 20 mg

Chonluten · 20 mg

Cortagen · 20 mg

Crystagen · 20 mg

Livagen · 20 mg

Ovagen · 20 mg

Pinealon · 20 mg

Prostamax · 20 mg

Testagen · 20 mg

Vesugen · 20 mg

Vilon · 20 mg

Endoluten · 20 mg oral

Cerluten · 20 mg oral

Ventfort · 20 mg oral

Libidon · 20 mg oral

Testoluten · 20 mg oral

Cognitive & Mood

Dihexa · 10 mg

Cognitive & Sleep

Adamax · 10 mg

Cerebrolysin · 60 mg

DSIP · 5 mg

DSIP · 10 mg

PE-22-28 · 10 mg

Selank · 5 mg

Selank · 10 mg

Semax · 5 mg

Semax · 10 mg

Cortexin · 10 mg

P21 · 10 mg

Davunetide · 5 mg

Retinalamin · 5 mg

N-Acetyl Semax Amidate · Intranasal (0.1% / 1%)

Dermorphin · 5 mg

Growth Hormone

CJC-1295 DAC · 2 mg

CJC-1295 DAC · 5 mg

CJC-1295 NO DAC · 5 mg

GHRP-2 · 5 mg

GHRP-2 · 10 mg

GHRP-6 · 2 mg

GHRP-6 · 5 mg

GHRP-6 · 10 mg

HGH 191AA · 10 IU

IGF-1 LR3 · 1 mg

Ipamorelin · 5 mg

Ipamorelin · 10 mg

MGF · 5 mg

Sermorelin · 5 mg

Sermorelin · 10 mg

Tesamorelin · 5 mg

Tesamorelin · 10 mg

Tesamorelin · 20 mg

AOD-9604 + CJC-1295 + Ipamorelin · 12 mg

CJC-1295 + GHRP-2 · 10 mg

CJC-1295 no DAC + Ipamorelin · 10 mg

Ipamorelin + Tesamorelin · 10 mg

CJC-1295 DAC + Ipamorelin · 2+5 mg

CJC-1295 DAC + Ipamorelin · 5+5 mg

MK-677 · 25 mg

Hexarelin · 5 mg

IGF-1 DES · 1 mg

PEG-MGF · 2 mg

EPO · 3000 IU

Healing & Recovery

Follistatin-344 · 1 mg

Wolverine stack · 10 mg + 10 mg blend vial (20 mg total)

ACE-031 · 1 mg

Teriparatide · 10 mg

Hormonal & Reproductive

Enclomiphene · 25 mg

Immune & Gut

Thymosin Alpha-1 · 5 mg

Thymosin Alpha-1 · 10 mg

Larazotide · 5 mg oral

Thymalin · 10 mg

VIP · 5 mg

Teduglutide · 5 mg

Thymogen · 10 mg

Thymulin · 5 mg

Longevity

Epithalon · 10 mg

FOXO4-DRI · 10 mg

Glutathione · 600 mg

MOTS-C · 5 mg

MOTS-C · 10 mg

MOTS-C · 20 mg

NAD+ · 500 mg

NAD+ · 1000 mg

PNC-27 · 30 mg

SS-31 · 10 mg

SS-31 · 30 mg

Vitamin B12 · 10 mg

Humanin · 5 mg

Metabolic & Weight

Liraglutide · 10 mg

Tesofensine · 0.5 mg capsule (research sizes 0.25 / 0.5 / 1 mg)

CagriSema · 5 mg / 5 mg combo vial

Pramlintide · 5 mg vial

Lipo-C · 10 mL multi-dose vial

Amycretin · 5 mg

VK2735 · 10 mg

Setmelanotide · 10 mg

Adipotide · 5 mg

Metabolic / GLP-1

5-Amino-1MQ · 10 mg

5-Amino-1MQ · 50 mg

AICAR · 50 mg

AOD-9604 · 2 mg

AOD-9604 · 5 mg

Cagrilintide · 5 mg

Cagrilintide · 10 mg

L-Carnitine · 200 mg

Mazdutide · 5 mg

Mazdutide · 10 mg

Retatrutide · 5 mg

Retatrutide · 6 mg

Retatrutide · 10 mg

Retatrutide · 12 mg

Retatrutide · 20 mg

Retatrutide · 24 mg

Retatrutide · 30 mg

Semaglutide · 5 mg

Semaglutide · 10 mg

Semaglutide · 20 mg

SLU-PP-332 · 5 mg

Survodutide · 10 mg

Tirzepatide · 5 mg

Tirzepatide · 10 mg

Tirzepatide · 15 mg

Tirzepatide · 30 mg

Cagrilintide + Semaglutide · 10 mg

Orforglipron · 6 mg

Pemvidutide · 5 mg

Ecnoglutide · 10 mg

Eloralintide · 10 mg

HGH Fragment 176-191 · 5 mg

Tirzepatide · 60 mg

Retatrutide · 60 mg

Dulaglutide · 5 mg

Repair & Recovery

Ara-290 · 16 mg

BPC-157 · 5 mg

BPC-157 · 10 mg

GHK-Cu · 50 mg

GHK-Cu · 100 mg

KPV · 10 mg

LL-37 · 5 mg

TB-500 · 5 mg

TB-500 · 10 mg

BPC-157 + TB-500 · 10 mg

BPC-157 + TB-500 · 20 mg

GLOW · 70 mg

KLOW · 80 mg

Tri-Heal (TB-500 + BPC-157 + KPV) · 45 mg

TB-500 + BPC-157 · 5+5 mg

Thymosin Beta-4 · 10 mg

Sexual & Hormonal

Gonadorelin · 2 mg

HCG · 5000 iu

HMG · 75 iu

Kisspeptin · 10 mg

Melanotan II · 10 mg

Oxytocin · 5 mg

Oxytocin · 10 mg

PT-141 · 10 mg

SNAP-8 · 10 mg

Melanotan II + PT-141 · 10+10 mg

Melanotan I · 10 mg

Triptorelin · 2 mg

Skin & Cosmetic

Argireline · 10% Topical Solution

Matrixyl 3000 · Topical serum (3-10% blend)

GHK (Copper-Free) · 50 mg

AHK-Cu · 50 mg

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04IGF-1 DES — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. IGF-1 DES is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Limitations and the Human-Evidence Gap

Every honest account of NAD+ and Parkinson’s disease converges on the same conclusion: the human evidence gap is wide, and the most important results are not yet in. It is worth cataloguing the specific limitations, because they are what separate a promising research program from a proven therapy, and because they are exactly the details that hype tends to omit. The first limitation is trial size and duration. The two completed randomized trials in Parkinson’s disease enrolled 30 and 20 participants and lasted 30 days and 4 weeks respectively.1,2 These are appropriate designs for their stated purposes, safety and target engagement, but they are structurally incapable of demonstrating disease modification, which manifests as a gradual divergence of progression curves over a year or more. Any clinical improvement seen in such short trials is more likely to reflect symptomatic effects, measurement variability, or confounding than a change in the underlying neurodegenerative process. The NR-SAFE authors’ own caution about levodopa-timing confounding their UPDRS signal is a model of the appropriate humility.2 The second limitation is the responder problem. NADPARK showed that oral NR raises brain NAD+ in some participants but not others, and that clinical and metabolic signals clustered in the responder subgroup.1 This heterogeneity is scientifically important but clinically double-edged: it means that even if NAD+ elevation helps, an intention-to-treat analysis that includes non-responders may dilute the effect below detectability, while a responder-only analysis risks the statistical pitfalls of post-hoc subgrouping. Sorting out who responds, why, and how to identify them in advance is unfinished work. The third limitation is the model-to-human translation gap already discussed. The mechanistic and preclinical case is strong, but Parkinson’s disease has an unusually long history of interventions that protected neurons in animals and then failed in rigorous human trials, from antioxidants to anti-apoptotic agents to other mitochondrial strategies. NAD+ boosting could be different, but the base rate argues for caution until the phase III data are published.1,5 The fourth limitation concerns the epidemiology: the cross-sectional NHANES analysis linking higher dietary niacin intake to lower Parkinson’s prevalence is consistent with the hypothesis but cannot establish causation, and the larger EPIC-based cohort study examined niacin and tryptophan intake against incident Parkinson’s disease without providing the kind of confirmed protective association that would strengthen the causal case.10,11 Observational designs of this type are in any event particularly vulnerable to reverse causation, because prodromal Parkinson’s disease alters diet, smell, appetite, and gastrointestinal function years before diagnosis. The fifth limitation is conceptual: “NAD+ deficiency” is not a single, cleanly measured, universally agreed entity in Parkinson’s disease. Different studies measure NAD+ in different tissues (brain, cerebrospinal fluid, blood, skeletal muscle) using different techniques, and these compartments do not move in lockstep. The finding of lower NAD+ or lower NAD+-synthesizing enzymes in some Parkinson’s tissues is real and reproducible in places, but whether it is a primary driver of neurodegeneration, a downstream consequence of mitochondrial failure, or both at once is not resolved.4,6 A therapy premised on correcting a deficiency needs a clear picture of what deficiency it is correcting and where. Until the NOPARK results and comparable trials are published and, ideally, independently replicated, the responsible bottom line is that NAD+ precursors remain an unproven, investigational approach in Parkinson’s disease, however biologically attractive the rationale.3

Source: dosagepeptide.com ↗

Research Models and How Lipogenesis Is Actually Measured

Understanding how AOD-9604 has been studied clarifies both what the data can support and what a real antilipogenic investigation would require. The methodology falls into three tiers, and only the first touches lipogenesis directly. Ex vivo and in vitro fat-tissue work. The foundational studies examined lipolysis and lipogenesis in adipose tissue and isolated fat cells, measuring free-fatty-acid and glycerol release, fat oxidation, and — critically — the activity of lipogenic enzymes such as acetyl-CoA carboxylase.23 Enzyme-activity assays of this kind are the appropriate tool for an antilipogenic claim, and they are the source of the strongest evidence that a C-terminal domain peptide can suppress fat synthesis. A more complete modern program would add radiolabeled- or deuterium-tracer incorporation into fatty acids to quantify DNL flux, plus expression of ACC, FASN, SREBP-1c, and ChREBP under the peptide. Rodent models. The most methodologically informative animal work is the β3-AR knockout study, a clean genetic approach that isolated the receptor’s contribution by comparing knockout and wild-type mice under identical treatment.4 Obese Zucker rats and ob/ob mice provided body-weight, fat-mass, and substrate-oxidation readouts.15 These are genetically obese metabolic models, well suited to whole-body fat-balance questions but blunt instruments for isolating lipogenesis from lipolysis, since net fat change reflects both. Human trials. The clinical methodology was appropriate for an obesity drug — randomized, double-blind, placebo-controlled designs with weight and body-composition endpoints, plus dedicated safety and pharmacokinetic studies.610 A safety and tolerability study specifically characterized the peptide in humans.6 But none of these used lipogenesis endpoints. To answer this article’s question in humans would require a purpose-built study: stable-isotope measurement of de novo lipogenesis, adipose and hepatic lipogenic-gene expression, and controlled dosing — work that has never been done for AOD-9604. The methodological bottom line is that the antilipogenic evidence is strongest exactly where it is least generalizable (isolated rodent fat-tissue enzyme assays) and absent exactly where it would matter most (human DNL flux). Until that gap is filled, any statement that AOD-9604 “reduces lipogenesis in humans” is hypothesis, not finding. Terminology used across this literature — lipogenesis, lipolysis, DNL, ACC, FASN — is defined for reference in the site’s peptide and metabolism glossary.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to Incorporate Peptide Blends in Your Wellness Protocol

Peptide blends represent one of the most sophisticated approaches to personalized wellness available today. Unlike single-peptide therapies that target one specific area of concern, peptide blends combine multiple bioactive compounds to address multiple health goals simultaneously, creating synergistic effects that amplify results across your entire wellness protocol. If you’re exploring how to integrate peptide blends into your health routine – whether for recovery, anti-aging, cognitive enhancement, or metabolic optimization – this guide will walk you through everything you need to know to make informed decisions and maximize your outcomes.

Source: puretestedpeptides.com ↗
Dosage reference

KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide

KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →